Table of Contents Table of Contents
Previous Page  110 / 112 Next Page
Information
Show Menu
Previous Page 110 / 112 Next Page
Page Background

108

NCCN Guidelines for Patients

®

Esophageal Cancer, Version 1.2016

Index

Index

2

nd

opinion

94

ablation

32, 34, 46–47, 68–69

biopsy

23, 26–27, 49, 55, 57, 71, 77, 79

cancer grade

17–18, 20

cancer stage

14, 18–20, 34, 90

chemoradiation

36, 46–47, 52–59, 64, 68–69, 74–81, 86

chemotherapy

36, 38–42, 47, 52–53, 55, 58–59, 63–64,

69, 74–77, 80–81, 84–86

clinical trial

41–42, 63, 85, 91

complementary and alternative medicine

37

complete blood count

23–24

comprehensive chemistry profile

23–24

computed tomography

23–25, 36, 38, 50, 55–57, 70, 72,

77–79

endoscopic resection

23, 27, 32–33

esophagectomy

34–35, 42, 46–47, 50–59, 64, 68–69,

72–74, 76–81, 86

HER2

23, 28, 40–41, 84–85

medical history

22–24, 48–51, 56–57, 64, 70–73, 78–79,

86

NCCN Member Institutions

106

NCCN Panel Members

105

nutrition

22, 29–30, 47, 50–51, 53, 56–57, 64, 69, 72–74,

78–79, 86

pathology report

17, 90, 94

performance status

61, 63, 83, 85

physical exam

23–24, 48–49, 50–51, 56–57, 64, 70–73,

78–79, 86

positron emission tomography

23, 25, 48, 50, 55–57, 70,

72, 77–79

radiation therapy

36–37, 42, 52–53, 63–64, 74–75, 85–86

shared decision-making

89, 96

supportive care

29, 46–47, 52–55, 58–61, 64, 68–69,

74–77, 80–83, 86

targeted therapy

39–42, 85

upper GI endoscopy

23, 26, 48–51, 55–57, 70–73, 77–79